[Advances in Anti-Dementia Therapies in Older Adults].

Deutsche medizinische Wochenschrift (1946)

Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.

European journal of gastroenterology & hepatology

Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis.

Case reports in medicine

DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.

Molecular therapy. Nucleic acids

Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.

Nepal journal of epidemiology

Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.

Journal of lipid and atherosclerosis

Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Popular obesity medications significantly lower overall cancer risk, study finds. The breakthrough class of obesity medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide, continue to make waves in modern medicine. https://t.co/Bul3Icqy4F

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

Retatrutide is a GLP-3. Triple agonist. Hits GLP-1, GIP, and glucagon receptors at once. In comparison: - Semaglutide (Ozempic): ~15% loss at 68 weeks - Tirzepatide (Zepbound): ~22% at 72 weeks - Retatrutide phase 3: ~28-30% at 80 weeks

RT @gemoscatelli: Fastest growing business/sales in 2026: weight loss, obesity, diabetes, GIP/GLP-1 agonists (tirzepatide and semaglutide)…